Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4167 | Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures Wiki | 1.00 |
| drug3502 | Saline Wiki | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003428 | Cross Infection NIH | 0.50 |
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
Description: solicited local and systemic AEs after vaccination
Measure: Incidence of solicited adverse events Time: Through 1 year post vaccinationDescription: unsolicited AEs after vaccination
Measure: Incidence of unsolicited adverse events Time: Through 1 year post vaccinationDescription: percentage of subjects with SAEs
Measure: Incidence of serious adverse events Time: Through 1 year post vaccinationDescription: Change from baseline in antigen-specific binding antibody titers
Measure: Geometric mean titer (GMT) of antigen-specific binding antibody titers Time: Through 1 year post vaccinationDescription: Seroconversion rate can be calculated based on test results reaching the quantifiable antibody level after vaccination
Measure: Percentage of subjects who seroconverted after vaccination Time: Through 1 year post vaccinationDescription: NAb is regarded as produced when FRNT50 is detected more than four times the baseline after vaccination
Measure: Geometric mean titer (GMT) of neutralizing antibody level Time: Through 1 year post vaccinationDescription: Change from baseline in antigen-specific binding antibody titers
Measure: Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers Time: Through 1 year post vaccinationDescription: Antigen-specific IFN-γ T cell immune response assessed before/after vaccination
Measure: Change from baseline in antigen-specific IFN-g cellular immune response Time: Through 1 year post vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports